 LOS ANGELES--BUSINESS WIRE--Second Sight Medical Products, Inc. NASDAQ: EYES Second Sight or the Company, a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of 5.00 per share, for gross proceeds of 50,000,000, before deducting underwriting discounts, commissions an 